Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Acucela Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, meaning each pending matter is being reviewed by a different individual. The portfolio is active across 2 distinct art units, suggesting that the company's pharmaceutical or biotech innovations are categorized into two primary technical specialties at the USPTO.
ALEXANDER, WILLIAM R is the busiest examiner for the company, currently overseeing 1 pending office action. Since each of the 4 pending office actions is with a different examiner, the workload is perfectly distributed across the examining staff. This lack of examiner concentration requires the company to navigate multiple distinct sets of examiner preferences and historical tendencies simultaneously. The presence of 2 distinct art units indicates that while the examiners are different, they are grouped into only two technical divisions, which may provide some consistency in broad examination policies.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALEXANDER, WILLIAM R | 1 | 87.9% | +7.0% |
| LUKJAN, SEBASTIAN X | 1 | 76.3% | +40.3% |
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18985550 | ELECTRONIC CASE FOR ELECTRONIC SPECTACLES | ALEXANDER, WILLIAM R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17934945 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | HUANG, GIGI GEORGIANA | 55d |
| 18379142 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | JAVANMARD, SAHAR | 56d |
| 18972217 | METHOD AND APPARATUS FOR TREATING REFRACTIVE ERROR OF THE EYE | LUKJAN, SEBASTIAN X | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18985550 | ELECTRONIC CASE FOR ELECTRONIC SPECTACLES | ALEXANDER, WILLIAM R | — | §103 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18972217 | METHOD AND APPARATUS FOR TREATING REFRACTIVE ERROR OF THE EYE | LUKJAN, SEBASTIAN X | — | DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18379142 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | JAVANMARD, SAHAR | 1622 | §103Other | Non-Final OA | 56d | Pending | Oct 11, 2023 |
| 17934945 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | HUANG, GIGI GEORGIANA | 1613 | Other | Final Rejection | 55d | Pending | Sep 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial